a 2012 0059

The invention relates to organic chemistry, namely to the synthesis of biologically active compounds from the group of hydrazinecar-bothioamides with heterocyclic nuclei which can be used for prevention and treatment of human myeloid leukemia.

Summary of the invention consists in that as an inhibitor of human myeloid leukemia (HL-60 cells) is proposed a new compound N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide with the formula:

The claimed compound possesses inhibitory properties of human myeloid leukemia.

Claims: 1